| Literature DB >> 35645675 |
Anna Sadowska-Przytocka1, Michalina Gruszczyńska2, Anna Ostałowska2, Patrycja Antosik2, Magdalena Czarnecka-Operacz1, Zygmunt Adamski1, Katarzyna Łącka3.
Abstract
Acne vulgaris is a very common skin disease being diagnosed in Westernized populations, however, its multifactorial etiopathogenesis still remains unclear. Recent research has demonstrated a possible linkage between acne and insulin resistance (IR), which is the topic of our review. In addition to an inappropriate diet, excessive androgen production or obesity, it is the IR which might be responsible for lack of efficacy of classical treatment strategy in acne. Interestingly, in all such cases an increased activity of mammalian target of rapamycin kinase complex 1 (mTORC1) has been detected. This observation might be considered as the basis of the possible role of metformin as an adjunct therapeutic modality for patients suffering from acne. The aim of our review is to present the possible etiological correlation between acne and insulin resistance, as well as metformin therapy, which might be highly useful in the treatment to resistant forms of acne. Copyright:Entities:
Keywords: acne vulgaris; insulin resistance; metformin; resistant acne
Year: 2021 PMID: 35645675 PMCID: PMC9131965 DOI: 10.5114/ada.2021.107101
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.664
HOMA values in acne patients and controls [9, 16, 44, 45]
| Para meter | Insulin resistance in severe acne vulgaris | Dietary glycemic factors, insulin resistance and adiponectin levels in acne vulgaris | Insulin resistance and metabolic syndrome in young men with acne | Insulin resistance in acne: a new risk factor for men? | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Nazan Emiroglu | Cerman | Nagpal | del Prete | ||||||||
| Group | Patients | Controls |
| Patients | Controls |
| Patients | Controls |
| Patients | Controls |
|
| Number | 243 | 156 | 50 | 36 | 100 | 100 | 22 | 22 | ||||
| Gender | 40.7% males | 28.8% males | 44% males | 38.9% males | 100% males | 100% males | 100% males | 100% males | ||||
| Age | 19.94 ±4.77 | 19.22 ±0.69 | 0.05 | 18.8 ±3.2 | 19.06 ±3.49 | 0.747 | 22.7 ±3.0 | 23.7 ±3.0 | 0.06 | 18.6 ±2.5 | 20.2 ±3 | 0.06 |
| BMI | 22.6 ±2.95 | 22.3 ±3.52 | 0.05 | 21.16 ±1.86 | 21.69 ±1.58 | 0.07 | 22.9 ±4.0 | 23.4 ±3.2 | 0.37 | 24 ±2.8 | 20.1 ±1.5 | 0.003 |
| Glucose | 82.91 ±9.8 | 80.26 ±8.4 | 0.111 | 84 ±7.72 | 83.67 ±8.33 | 0.849 | 88.2 ±8.3 | 84.5 ±11.2 | 0.008 | 88.9 ±7.8 | 84.3 ±5.9 | 0.03 |
| Insulin | 14.01 ±11.99 | 9.12 ±3.55 | 0.001 | 9.72 ±6.26 | 9.88 ±4.3 | 0.384 | 9.2 ±8.5 | 7.8 ±6.8 | 0.22 | 10.6 ±8.4 | 5.5 ±1.4 | 0.01 |
| HOMA | 2.87 ±2.572 | 1.63 ±0.663 | 0.001 | 2.03 ±1.49 | 2.05 ±0.93 | 0.37 | 2.0 ±1.8 | 1.7 ±2.3 | 0.04 | 1.7 ±0.8 | 1.1 ±0.3 | 0.016 |
Figure 1Correlation between IR and acne
Figure 2Classical methods for treatment of acne
Review of the effectiveness of metformin treatment in acne vulgaris patients [64–67]
| Parameter | The effect of metformin in the treatment of intractable and late onset acne: a comparison with oral isotretinoin | Low glycamic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments | DB-RCT on the efficacy and safety of metformin adjunct to lymecyclie and topical adapalen/BPGel in mod-severe acne | Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris a randomized open-labeled study | ||||
|---|---|---|---|---|---|---|---|---|
| Author, date | Behrangi | G. Fabbrocini | Nina Gabaton, 2016 | Robinson | ||||
| Group | Metformin | Isotretinoin | Metformin | Controls | Metformin | Controls | Metformin | Controls |
| Number, gender | 35 females | 35 females | 10 males | 10 males | 20 M/F | 20 M/F | 42 | 42 |
| Age | 32.2 ±4.3 | 17–24 (19.5) | 16–45 | |||||
| Medications provided | Metformin 2 × 500 mg | Isotretinoin 1 × 20 mg | Metformin 2 × 500 mg | Azelaic acid, nicotinamid | Metformin Adapalen/BPGel | Placebo | Metformin 1 × 850 mg | Tetracycline 250 mg |
| Time | 6 months | 6 months | 18 weeks | 12 weeks | ||||
| Acne T° | GAGS = 31.9 | GAGS = 34.1 | GAGS = 25.1 ±8.9 | GAGS = 24.9 ±7.6 | ||||
| Acne improval | GAGS = 24.6, PCOS-GAGS = 13.5 | GAGS = 13.3, PCOS-GAGS = 24.2 | GAGS = 14.1 ±10.4 | GAGS = 19.4 ±7.4 | Higher reduction of the inflammatory and total lesion count | CADI index reduce of 4.82 | CADI index reduce of 4.22 | |
| Extra effects | Increased HDL, decreased LDL, FBS | Increased AST, ALT, bilirubin | Increased HDL | Self-limited systemic adverse events (diarrhea, flatulence, headache, epigastric pain) | Gastrointestinal symptoms in 31.7% | |||